dc.contributor.author | Veselá, Kateřina | |
dc.contributor.author | Kejík, Zdeněk | |
dc.contributor.author | Abramenko, Nikita | |
dc.contributor.author | Kaplánek, Robert | |
dc.contributor.author | Jakubek, Milan | |
dc.contributor.author | Petrlova, Jitka | |
dc.date.accessioned | 2024-12-11T10:10:48Z | |
dc.date.available | 2024-12-11T10:10:48Z | |
dc.date.issued | 2024 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14178/2753 | |
dc.description.abstract | The concept of intratumoral microbiota is gaining attention in current research. Tumor-associated microbiota can activate oncogenic signaling pathways such as NF-kappa B, thereby promoting tumor development and progression. Numerous studies have demonstrated that curcumin and its analogs possess strong antitumor effects by targeting the NF-kappa B signaling pathway, along with potent antibacterial properties. In this study, we tested the antibacterial activity of two curcuminoids, Py-cPen and V-cPen, against the Gram-negative bacterial strains Pseudomonas aeruginosa and Escherichia coli and the Gram-positive bacterial strain Streptococcus aureus using in vitro assays and fluorescent microscopy. We observed that both Py-cPen and V-cPen reduced NF-kappa B activation upon lipopolysacharide (LPS) challenge in cell assays. In addition, our findings indicate that Py-cPen and V-cPen interact with LPS, as demonstrated by transmission electron microscopy and confirmed using in silico analyses, thereby modulating LPS activity. Overall, our data indicate that Py-cPen and V-cPen exhibit strong antibacterial and antiinflammatory properties, suggesting their potential as candidates for new multitarget therapeutic strategies. | en |
dc.language.iso | en | |
dc.relation.url | https://doi.org/10.3389/fmed.2024.1478122 | |
dc.rights | Creative Commons Uveďte původ 4.0 International | cs |
dc.rights | Creative Commons Attribution 4.0 International | en |
dc.title | Investigating antibacterial and anti-inflammatory properties of synthetic curcuminoids | en |
dcterms.accessRights | openAccess | |
dcterms.license | https://creativecommons.org/licenses/by/4.0/legalcode | |
dc.date.updated | 2025-01-15T10:11:15Z | |
dc.subject.keyword | curcuminoids | en |
dc.subject.keyword | antibacterial | en |
dc.subject.keyword | anti-inflammatory | en |
dc.subject.keyword | immunomodulatory | en |
dc.subject.keyword | lipopolysaccharide | en |
dc.subject.keyword | | en |
dc.identifier.eissn | 2296-858X | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5102 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//LX22NPO5107 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//SVV260637 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM//SVV260521 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/UNCE/MED/UNCE/MED/007 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/UK/COOP/COOP | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MSM/LM/LM2023053 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/TA0/TN/TN02000109 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU22-08-00160 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU21-08-00407 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/TA0/TN/TN02000109 | |
dc.relation.fundingReference | info:eu-repo/grantAgreement/MZ0/NU/NU21-08-00407 | |
dc.date.embargoStartDate | 2025-01-15 | |
dc.type.obd | 73 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | |
dc.identifier.doi | 10.3389/fmed.2024.1478122 | |
dc.identifier.utWos | 001352016800001 | |
dc.identifier.eidScopus | 2-s2.0-85208788038 | |
dc.identifier.obd | 656303 | |
dc.identifier.pubmed | 39534226 | |
dc.subject.rivPrimary | 30000::30100 | |
dcterms.isPartOf.name | Frontiers in Medicine | |
dcterms.isPartOf.issn | 2296-858X | |
dcterms.isPartOf.journalYear | 2024 | |
dcterms.isPartOf.journalVolume | 11 | |
dcterms.isPartOf.journalIssue | October | |
uk.faculty.primaryId | 108 | |
uk.faculty.primaryName | 1. lékařská fakulta | cs |
uk.faculty.primaryName | First Faculty of Medicine | en |
uk.department.primaryId | 100025448551 | |
uk.department.primaryName | BIOCEV 1. lékařské fakulty | cs |
uk.department.primaryName | BIOCEV of the 1st Faculty of Medicine | en |
uk.department.secondaryId | 1522 | |
uk.department.secondaryName | Klinika pediatrie a dědičných poruch metabolismu 1. LF a VFN | cs |
uk.department.secondaryName | Department of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFN | en |
dc.type.obdHierarchyCs | ČLÁNEK V ČASOPISU::článek v časopisu::původní článek | cs |
dc.type.obdHierarchyEn | JOURNAL ARTICLE::journal article::original article | en |
dc.type.obdHierarchyCode | 73::152::206 | en |
uk.displayTitle | Investigating antibacterial and anti-inflammatory properties of synthetic curcuminoids | en |